Investor Presentation Q1 2023

60 Investor presentation First three months of 2023 In STEP 4, people treated with semaglutide had a superior weight loss of up to 18.2% STEP 4 showed significantly greater weight loss post run-in than placebo % change in body weight 0 Randomisation • Data from STEP 4 Average age 46 . 79% women -4 -8 I I -12 -10.5% -16 I I Placebo: -5.2% 目 • Average BMI - 38.4 kg/m2 Trial highlights that obesity is a chronic disease requiring sustained treatment Novo NordiskⓇ Semaglutide 2.4 mg: -18.2% Improvements on a panel of cardiovascular risk markers -20 048 12 16 20 24 28 36 44 52 60 68 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand; BMI: body mass index

View entire presentation